{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:30:12Z","timestamp":1781285412881,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.anndiagpath.2022.151953","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T12:15:56Z","timestamp":1650543356000},"page":"151953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["HER2 testing in metastatic breast cancer \u2013 Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?"],"prefix":"10.1016","volume":"59","author":[{"given":"Christopher R.","family":"Liwski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu C.","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny J.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian C.","family":"Bethune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.anndiagpath.2022.151953_bb0005","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151953_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti\u2013HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"issue":"45","key":"10.1016\/j.anndiagpath.2022.151953_bb0015","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.anndiagpath.2022.151953_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.anndiagpath.2022.151953_bb0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.6004\/jnccn.2012.0086","article-title":"Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines","volume":"10","author":"Carlson","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.anndiagpath.2022.151953_bb0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.anndiagpath.2022.151953_bb0035","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.anndiagpath.2022.151953_bb0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151953_bb0045","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomized controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151953_bb0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10549-015-3475-3","article-title":"Optimizing HER2 assessment in breast cancer: application of automated image analysis","volume":"152","author":"Holten-Rossing","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.anndiagpath.2022.151953_bb0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2022.151953_bb0060","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.anndiagpath.2022.151953_bb0065","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151953_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurillio","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.anndiagpath.2022.151953_bb0075","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151953_bb0080","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.anndiagpath.2022.151953_bb0085","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2022.151953_bb0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1634\/theoncologist.2010-0059","article-title":"Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis","volume":"15","author":"Pusztai","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.anndiagpath.2022.151953_bb0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4048\/jbc.2019.22.e38","article-title":"Changes in biomarker status in metastatic breast cancer and their prognostic value","volume":"22","author":"Woo","year":"2019","journal-title":"J Breast Cancer"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151953_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-018-4101-7","article-title":"Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options","volume":"18","author":"McAnena","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151953_bb0105","first-page":"515","article-title":"Discordance of the estrogen receptor and HER-2\/neu in breast cancer from primary lesion to first and second metastatic site","volume":"9","author":"Lower","year":"2017","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.anndiagpath.2022.151953_bb0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer","volume":"30","author":"Amir","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151953_bb0115","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.asjsur.2020.05.032","article-title":"Receptor discordance and phenotype change in metastatic breast cancer","volume":"44","author":"Kao","year":"2021","journal-title":"Asian J Surg"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151953_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-020-05935-5","article-title":"Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer","volume":"185","author":"Van Raemdonck","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151953_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mds248","article-title":"Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis","volume":"24","author":"Dieci","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2022.151953_bb0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","article-title":"Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors","volume":"30","author":"Niikura","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2022.151953_bb0135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ctrv.2013.05.003","article-title":"HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact","volume":"39","author":"Turner","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151953_bb0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-008-9931-6","article-title":"HER-2\/neu expression in primary and metastatic breast cancer","volume":"113","author":"Lower","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.anndiagpath.2022.151953_bb0145","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.prp.2018.10.015","article-title":"Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer","volume":"214","author":"Jakobsen","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"6","key":"10.1016\/j.anndiagpath.2022.151953_bb0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/his.13812","article-title":"What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice?A study with multiple platforms","volume":"74","author":"Koopman","year":"2019","journal-title":"Histopathology"},{"issue":"17","key":"10.1016\/j.anndiagpath.2022.151953_bb0155","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low\u2013expressing advanced breast cancer: results from a phase ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.anndiagpath.2022.151953_bb0160","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:28Z","timestamp":1761078868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913422000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"alternative-id":["S1092913422000557"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151953","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 testing in metastatic breast cancer \u2013 Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151953"}}